HR 3906 Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Medical Research for Our Troops Act
To amend the Full-Year Continuing Appropriations and Extensions Act, 2025 to restore amounts available for Defense Health Agency research, development, test, and evaluation, including Congressionally Directed Medical Research Programs.
Summary
- Amends Section 1407(1) of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119-4) to raise the funding amount for Defense Health Agency research, development, test, and evaluation from $40,395,072,000 to $41,576,684,000.
- Removes the additional text that followed the original dollar amount in Section 1407(1), so the provision ends with a period.
- Makes the change effective as if it had been included in the original enactment of Public Law 119-4.
- Requires that funds for Congressionally Directed Medical Research Programs be implemented at levels and in a manner consistent with the Consolidated Appropriations Act, 2024 (Public Law 118-47).
- Directs the Secretary of Defense to use those funds to support the research programs, peer-reviewed initiatives, and projects identified in the explanatory statement accompanying Public Law 118-47, and to follow the funding allocations and research priorities on pages 311 through 314 of that statement.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
Rep. Carson, André (D-IN) [#7]
52 cosponsors
-
Del. Norton, Eleanor Holmes (D-DC) [At-large] -
Rep. Auchincloss, Jake (D-MA) [#4] -
Rep. Balint, Becca (D-VT) [At-large] -
Rep. Barragán, Nanette Diaz (D-CA) [#44] -
Rep. Beatty, Joyce (D-OH) [#3] -
Rep. Bell, Wesley (D-MO) [#1] -
Rep. Bishop, Sanford D. (D-GA) [#2] -
Rep. Budzinski, Nikki (D-IL) [#13] -
Rep. Cohen, Steve (D-TN) [#9] -
Rep. Craig, Angie (D-MN) [#2] -
Rep. Davids, Sharice (D-KS) [#3] -
Rep. Davis, Danny K. (D-IL) [#7] -
Rep. Deluzio, Christopher R. (D-PA) [#17] -
Rep. Doggett, Lloyd (D-TX) [#37] -
Rep. Fields, Cleo (D-LA) [#6] -
Rep. Figures, Shomari (D-AL) [#2] -
Rep. Foster, Bill (D-IL) [#11] -
Rep. Garamendi, John (D-CA) [#8] -
Rep. García, Jesús G. "Chuy" (D-IL) [#4] -
Rep. Garcia, Sylvia R. (D-TX) [#29] -
Rep. Goodlander, Maggie (D-NH) [#2] -
Rep. Gottheimer, Josh (D-NJ) [#5] -
Rep. Grijalva, Adelita S. (D-AZ) [#7] -
Rep. Horsford, Steven (D-NV) [#4] -
Rep. Jackson, Jonathan L. (D-IL) [#1] -
Rep. Johnson, Henry C. "Hank" (D-GA) [#4] -
Rep. Johnson, Julie (D-TX) [#32] -
Rep. Levin, Mike (D-CA) [#49] -
Rep. Lynch, Stephen F. (D-MA) [#8] -
Rep. Matsui, Doris O. (D-CA) [#7] -
Rep. McBride, Sarah (D-DE) [At-large] -
Rep. McClain Delaney, April (D-MD) [#6] -
Rep. McGarvey, Morgan (D-KY) [#3] -
Rep. McIver, LaMonica (D-NJ) [#10] -
Rep. Moulton, Seth (D-MA) [#6] -
Rep. Mrvan, Frank J. (D-IN) [#1] -
Rep. Neal, Richard E. (D-MA) [#1] -
Rep. Ocasio-Cortez, Alexandria (D-NY) [#14] -
Rep. Olszewski, Johnny (D-MD) [#2] -
Rep. Pettersen, Brittany (D-CO) [#7] -
Rep. Ross, Deborah K. (D-NC) [#2] -
Rep. Salinas, Andrea (D-OR) [#6] -
Rep. Schrier, Kim (D-WA) [#8] -
Rep. Sewell, Terri A. (D-AL) [#7] -
Rep. Simon, Lateefah (D-CA) [#12] -
Rep. Soto, Darren (D-FL) [#9] -
Rep. Strickland, Marilyn (D-WA) [#10] -
Rep. Titus, Dina (D-NV) [#1] -
Rep. Tonko, Paul (D-NY) [#20] -
Rep. Trahan, Lori (D-MA) [#3] -
Rep. Williams, Nikema (D-GA) [#5] -
Rescom. Hernández, Pablo Jose (D-PR) [At-large]
Actions (3)
- Jun 11, 2025 Referred to the House Committee on Appropriations. · house
- Jun 11, 2025 Introduced in House
- Jun 11, 2025 Sponsor introductory remarks on measure. (CR E561)
Full text
IN THE HOUSE OF REPRESENTATIVES
June 11, 2025
Mr. Carson (for himself, Mr. Auchincloss, Ms. Barragan, Ms. Budzinski, Ms. Craig, Mr. Doggett, Mr. Fields, Ms. Garcia of Texas, Ms. Goodlander, Mr. Gottheimer, Mr. Jackson of Illinois, Mr. Levin, Mr. Lynch, Ms. McBride, Mrs. McIver, Mr. Moulton, Mr. Mrvan, Ms. Ocasio- Cortez, Mr. Neal, Ms. Norton, Ms. Ross, Ms. Salinas, Ms. Schrier, and Ms. Strickland) introduced the following bill; which was referred to the Committee on Appropriations
A BILL
To amend the Full-Year Continuing Appropriations and Extensions Act, 2025 to restore amounts available for Defense Health Agency research, development, test, and evaluation, including Congressionally Directed Medical Research Programs.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Medical Research for Our Troops Act”.
SEC. 2. RESTORATION OF AMOUNTS FOR DEFENSE HEALTH AGENCY RESEARCH, DEVELOPMENT, TEST, AND EVALUATION.
(a) In General.—Section 1407(1) of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119-4) is amended—
(1) by striking “$40,395,072,000” and inserting “$41,576,684,000”; and
(2) by striking the 23rd comma and all that follows through the period at the end and inserting a period.
(b) Effective Date.—The amendments made by subsection (a) shall take effect as if included in the enactment of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119-4).
(c) Congressionally Directed Medical Research Programs.—The funds made available for Congressionally Directed Medical Research Programs pursuant to section 1407(1) of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119-4), as amended by subsection
(a), shall be implemented in levels and in a manner consistent with the Consolidated Appropriations Act, 2024 (Public Law 118-47). The Secretary of Defense shall—
(1) ensure that such funds are used to support all research programs, peer-reviewed initiatives, and projects identified in the explanatory statement accompanying the Consolidated Appropriations Act, 2024 (Public Law 118-47); and
(2) obligate and expend such funds in a manner that preserves program continuity, including adherence to all specified funding allocations and research priorities identified on pages 311 through 314 of such explanatory statement. <all>
Comments